It is widely accepted that CXCR1 and CXCR2 are essential for the initiation and growth of human tumors, thus serve as the novel therapeutic targets for many solid tumors, including lung cancer, breast cancer, prostate cancer, ovarian cancer, liver cancer and melanoma. This evidence concerns the gene CXCR1 and prostate carcinoma.